BOGANI, COSTANZA
 Distribuzione geografica
Continente #
EU - Europa 1.958
NA - Nord America 1.936
AS - Asia 245
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
SA - Sud America 1
Totale 4.146
Nazione #
US - Stati Uniti d'America 1.934
PL - Polonia 1.040
RU - Federazione Russa 352
SE - Svezia 145
IE - Irlanda 128
IT - Italia 119
CN - Cina 74
SG - Singapore 64
DE - Germania 43
HK - Hong Kong 33
IN - India 33
GB - Regno Unito 29
UA - Ucraina 28
FI - Finlandia 27
CH - Svizzera 21
VN - Vietnam 15
JO - Giordania 12
BE - Belgio 9
TR - Turchia 8
ES - Italia 5
FR - Francia 5
AE - Emirati Arabi Uniti 4
CI - Costa d'Avorio 4
CA - Canada 2
LT - Lituania 2
AT - Austria 1
AU - Australia 1
DK - Danimarca 1
EE - Estonia 1
EU - Europa 1
KR - Corea 1
NL - Olanda 1
PE - Perù 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 4.146
Città #
Warsaw 1.040
Santa Clara 567
Fairfield 202
Chandler 137
Dublin 128
Ashburn 103
Woodbridge 101
Houston 89
Seattle 89
Cambridge 75
Wilmington 72
Ann Arbor 59
Jacksonville 55
Singapore 55
Beijing 40
Lawrence 33
Altamura 30
Princeton 30
Buffalo 25
Bern 21
Florence 21
Boston 20
Boardman 18
Pune 18
Bremen 15
Dong Ket 15
Hong Kong 15
Mumbai 15
Shanghai 14
San Diego 10
Brussels 9
Medford 9
Izmir 6
Phoenix 6
Salerno 6
Andover 5
Rignano sull'Arno 5
Abidjan 4
Cagliari 4
Falls Church 4
Los Angeles 4
New York 4
Norwalk 4
Prato 4
Abu Dhabi 3
Basauri 3
Cavriago 3
Frankfurt Am Main 3
Hillsboro 3
Kent 3
Naples 3
Ariano Irpino 2
Barcelona 2
Bitonto 2
Caldiero 2
Cremona 2
Hangzhou 2
Hebei 2
Helsinki 2
London 2
Milan 2
Montevarchi 2
Redwood City 2
San Jose 2
Toronto 2
West Jordan 2
Acton 1
Auburn Hills 1
Bratislava 1
Buccinasco 1
Canaan 1
Candiolo 1
Cinisello Balsamo 1
Clifton 1
Dallas 1
Dearborn 1
Forlì 1
Fuzhou 1
Jinan 1
Laurel 1
Lima 1
Moscow 1
Munich 1
Newark 1
Old Bridge 1
Palermo 1
Perth 1
Prescot 1
Radcliffe 1
Rome 1
Romola 1
Rotterdam 1
Seoul 1
Sesto Fiorentino 1
Southwark 1
Vienna 1
Vilnius 1
Washington 1
Xuzhou 1
Yubileyny 1
Totale 3.271
Nome #
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 279
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives 273
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial 269
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. 264
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis 263
Caratterizzazione di alterazioni molecolari relative alla patogenesi delle Neoplasie Mieloproliferative Croniche 254
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 238
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. 229
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 191
Overexpression of microRNA-16-2 contributes to the abnormalerythropoiesis in polycythemia vera. 163
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 151
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 141
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 137
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis 134
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. 134
Mitochondrial expression and functional activity of Breast Cancer Resistance Protein in different multiple drug-resistant cell lines 130
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. 129
Inconsistencies in the association between the JAL2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases 126
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. 118
Preclinical models for drug selection in myeloproliferative neoplasms. 110
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis. 100
Breast cancer resistance protein (BCRP) expression and activity in mitochondria of different multiple drug-resistant (MDR) cancer cell lines 93
JAK PI3K/mTOR COMBINATION THERAPY 91
Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis 90
mTOR/JAK INHIBITOR COMBINATION THERAPY 80
Totale 4.187
Categoria #
all - tutte 9.499
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.499


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020441 0 0 0 0 0 73 67 95 64 56 79 7
2020/2021445 42 43 18 65 22 46 21 34 41 55 27 31
2021/2022228 7 12 31 11 9 13 5 16 8 12 47 57
2022/2023572 48 112 26 57 49 93 67 43 40 6 8 23
2023/2024203 6 20 27 18 22 58 3 31 2 2 8 6
2024/20251.088 23 139 86 193 422 225 0 0 0 0 0 0
Totale 4.187